Dr Agarwal's Eye Hospital Limited has scheduled its 32nd Annual General Meeting (AGM) for September 9, 2026. The company notified shareholders of the upcoming meeting through advertisements published on August 15, 2026, in the English newspaper Financial Express and the Tamil newspaper Makkal Kural.

The notice includes details regarding the record date and instructions for electronic voting. Shareholders can access further information on the company's official website.

Meenakshi Jayaraman, Company Secretary and Compliance Officer, signed the communication confirming the dispatch of the notice to BSE Limited.

Dr. Agarwal's Eye Hospital reported a 35% year-on-year increase in standalone net profit to ₹23.38 crore for the quarter ended June 30, 2026 (Q1FY27), driven by a 22% surge in revenue from operations to ₹142.97 crore. The strong bottom-line growth underscores the company’s operational efficiency despite a slight compression in EBITDA margins. The Board of Directors approved the unaudited financial results and the limited review report issued by statutory auditors S.R. Batliboi & Associates LLP during a meeting held on August 03, 2026.

Q1FY27 Financial Performance

The company’s top-line expansion was broad-based, with revenue from operations rising from ₹116.92 crore in Q1FY26 to ₹142.97 crore in Q1FY27. This growth trajectory contributed to a significant improvement in earnings before interest, taxes, depreciation, and amortization (EBITDA), which climbed to ₹45.22 crore from ₹37.93 crore in the corresponding period last year. However, the EBITDA margin contracted slightly to 31.63% from 32.44%, indicating that operating costs grew at a marginally higher pace than revenue.

Profitability and Operational Insights

Net profit after tax for the quarter stood at ₹23.38 crore, compared to ₹17.26 crore in Q1FY26. The effective tax rate remained stable, with total tax expense recorded at ₹7.58 crore against a profit before tax of ₹30.96 crore. Earnings per share (EPS) increased to ₹48.38 from ₹36.72 in the year-ago quarter, reflecting enhanced value creation for shareholders. The company continues to operate in a single segment focused on eye care-related sales and services, with no additional disclosures required under Ind AS 108.

Corporate Developments

In addition to approving the financial results, the Board re-appointed M/s. B Y & Associates, Practicing Cost Accountants (Firm Registration No. 003498), as the Cost Auditors for the financial year 2026-27. This appointment was made in accordance with Section 148 of the Companies Act, 2013, and the Companies (Cost Records and Audit) Rules, 2014, as recommended by the Audit Committee. The cost auditors will hold office until the earlier of 180 days from the closure of FY27 or the submission of the cost audit report.

Strategic Context

The company remains subject to the final sanction of the Hon’ble NCLT, Chennai Bench, regarding its proposed scheme of amalgamation with its holding company, Dr. Agarwal’s Health Care Limited. Shareholder and creditor approvals for the scheme were obtained on July 02, 2026. Furthermore, the company has utilized ₹28.20 crore of the ₹70 crore raised through a preferential allotment to Dr. Agarwal’s Health Care Limited, with the balance temporarily invested in debt mutual funds as of June 30, 2026.